Brown Advisory Inc. Acquires 7,226 Shares of Biohaven Ltd. (NYSE:BHVN)

Brown Advisory Inc. raised its stake in Biohaven Ltd. (NYSE:BHVN) by 0.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 975,585 shares of the company’s stock after buying an additional 7,226 shares during the quarter. Brown Advisory Inc. owned about 0.96% of Biohaven worth $36,438,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in BHVN. Barclays PLC lifted its position in Biohaven by 87.6% in the 3rd quarter. Barclays PLC now owns 268,077 shares of the company’s stock valued at $13,396,000 after acquiring an additional 125,189 shares in the last quarter. Franklin Resources Inc. boosted its position in shares of Biohaven by 0.5% during the third quarter. Franklin Resources Inc. now owns 79,705 shares of the company’s stock worth $4,206,000 after buying an additional 412 shares during the period. JPMorgan Chase & Co. grew its holdings in shares of Biohaven by 85.4% during the third quarter. JPMorgan Chase & Co. now owns 809,448 shares of the company’s stock worth $40,448,000 after buying an additional 372,737 shares in the last quarter. Diversified Trust Co grew its holdings in shares of Biohaven by 16.6% during the fourth quarter. Diversified Trust Co now owns 5,585 shares of the company’s stock worth $209,000 after buying an additional 795 shares in the last quarter. Finally, Weybosset Research & Management LLC lifted its stake in Biohaven by 23.9% in the 4th quarter. Weybosset Research & Management LLC now owns 13,645 shares of the company’s stock valued at $510,000 after acquiring an additional 2,635 shares in the last quarter. Institutional investors and hedge funds own 88.78% of the company’s stock.

Insider Activity at Biohaven

In other Biohaven news, Director John W. Childs bought 32,700 shares of the stock in a transaction dated Tuesday, March 4th. The shares were bought at an average cost of $30.47 per share, with a total value of $996,369.00. Following the completion of the acquisition, the director now owns 2,320,571 shares of the company’s stock, valued at $70,707,798.37. This trade represents a 1.43 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. 16.00% of the stock is currently owned by corporate insiders.

Biohaven Stock Performance

NYSE BHVN opened at $22.59 on Tuesday. The stock has a market cap of $2.31 billion, a PE ratio of -2.42 and a beta of 1.18. The firm has a 50-day moving average of $24.61 and a 200-day moving average of $36.15. Biohaven Ltd. has a 52-week low of $15.79 and a 52-week high of $55.70.

Biohaven (NYSE:BHVN) last issued its quarterly earnings data on Monday, March 3rd. The company reported ($1.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.56) by ($0.29). As a group, analysts predict that Biohaven Ltd. will post -8.9 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently issued reports on BHVN. HC Wainwright reiterated a “buy” rating and issued a $54.00 price objective on shares of Biohaven in a report on Tuesday, March 4th. Robert W. Baird cut their price target on shares of Biohaven from $60.00 to $57.00 and set an “outperform” rating on the stock in a research report on Monday, April 28th. Morgan Stanley decreased their price objective on Biohaven from $69.00 to $63.00 and set an “overweight” rating for the company in a report on Friday, March 7th. Deutsche Bank Aktiengesellschaft set a $60.00 target price on Biohaven and gave the stock a “buy” rating in a report on Thursday, March 20th. Finally, JPMorgan Chase & Co. lowered their price target on Biohaven from $72.00 to $68.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 5th. Fourteen research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $62.54.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.